BioXcel Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast

Rhea-AI Summary

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) announced a conference call on November 12, 2020, at 8:30 AM ET to discuss its Q3 2020 financial and operational results. The conference will include a webcast accessible via the company's website. BioXcel is focused on drug development using AI to enhance therapies in neuroscience and immuno-oncology, with advanced programs like BXCL501 for neuropsychiatric agitation and BXCL701 targeting rare prostate cancer and pancreatic cancer. The call aims to provide insights into recent developments and future outlook.

Positive

• BioXcel's innovative approach utilizes artificial intelligence for drug development.
• Two advanced programs (BXCL501 and BXCL701) are focusing on significant medical needs.

Negative

• None.

NEW HAVEN, Conn., Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Thursday, November 12, 2020 at 8:30 AM Eastern Time to discuss its third quarter 2020 operating and financial results.

Conference Call & Webcast Details
Date/Time: Thursday, November 12, 2020, 8:30 AM Eastern Time
Domestic: 877-407-2985
International: 201-378-4915
The webcast will be accessible* under "Events" on the News & Media page of the Company's website at www.bioxceltherapeutics.com.

Replay
Domestic: 877-660-6853
International: 201-612-7415
Conference ID: 13712147
*Replay available through at least November 26, 2020

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit www.bioxceltherapeutics.com.

Contact Information:

BioXcel Therapeutics, Inc.
www.bioxceltherapeutics.com

Investor Relations:
John Graziano
jgraziano@troutgroup.com
1.646.378.2942

Media:
Julia Deutsch
jdeutsch@troutgroup.com
1.646.378.2967

FAQ

What is the date and time of BioXcel Therapeutics' Q3 2020 earnings call?

The Q3 2020 earnings call is scheduled for November 12, 2020, at 8:30 AM Eastern Time.

How can I access the BioXcel Therapeutics conference call?

The conference call can be accessed domestically at 877-407-2985 and internationally at 201-378-4915. A webcast will also be available on the company's website.

What are the main focuses of BioXcel Therapeutics?

BioXcel Therapeutics focuses on drug development in neuroscience and immuno-oncology, leveraging AI to identify new therapies.

What are the investigational products being developed by BioXcel Therapeutics?

The main investigational products are BXCL501 for neuropsychiatric agitation and BXCL701 for rare prostate cancer and pancreatic cancer.